This study is in progress, not accepting new patients
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
Summary
- Eligibility
- for people ages 2-17 (full criteria)
- Location
- at UCSF
- Dates
- study startedcompletion around
- Principal Investigator
- by Emmanuelle Waubant (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Emmanuelle Waubant (ucsf)
Dr Waubant trained as a neurologist in Toulouse, France. She continued her training as a neuroimmunology fellow in Dr Stephen Hauser’s UCSF laboratory, focusing on matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP), and their role in migration of lymphocytes through equivalents of the blood-brain barrier.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Alexion Pharmaceuticals, Inc.
- ID
- NCT04155424
- Phase
- Phase 2/3 Neuromyelitis Optica Spectrum Disorders Research Study
- Study Type
- Interventional
- Participants
- Expecting 12 study participants
- Last Updated